Literature DB >> 9010026

Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours.

R M Phillips1, M R Clayton.   

Abstract

A commonly used technique for evaluating potential bioreductive drugs is the determination of hypoxic cytotoxicity ratios in vitro. This experimental model, however, does not accurately mimic the tumour microenvironment, as other factors (such as reduced pH, poor nutrient status, low cell proliferation rates and high catabolite concentrations) are not incorporated into the design of the assay. Plateau-phase monolayer cultures possess many of these characteristics, and this study compared the response of plateau-phase and exponentially growing human colon carcinoma cells (DLD-1) with a series of standard and bioreductive compounds. All drugs tested were added directly to conditioned medium and three patterns of chemosensitivity were observed. In the case of doxorubicin, vinblastine and 5-fluorouracil, exponentially growing cells were significantly more responsive than plateau-phase cultures. ThioTEPA and MeDZQ (2,5-diaziridinyl-1, 4-benzoquinone) were equally cytotoxic to both populations of cells. Tirapazamine (SR4233), RSU 1069, mitomycin C and EO-9, however, were preferentially toxic towards plateau-phase compared with exponentially growing cells. While the exact mechanisms responsible for these observations in each case are not known, this study suggests that plateau-phase cultures may prove to be a useful experimental model in the evaluation of drugs designed to work preferentially within the tumour microenvironment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010026      PMCID: PMC2063287          DOI: 10.1038/bjc.1997.33

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures.

Authors:  P E Pizao; G J Peters; J Van Ark-Otte; L A Smets; E Smitskamp-Wilms; B Winograd; H M Pinedo; G Giaccone
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 2.  A critical appraisal of the predictive value of in vitro chemosensitivity assays.

Authors:  R M Phillips; M C Bibby; J A Double
Journal:  J Natl Cancer Inst       Date:  1990-09-19       Impact factor: 13.506

3.  Evaluation of bioreductive drugs in multicell spheroids.

Authors:  R E Durand; P L Olive
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells.

Authors:  P J O'Dwyer; K S Yao; P Ford; A K Godwin; M Clayton
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

5.  Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival.

Authors:  M C Pagliacci; F Spinozzi; G Migliorati; G Fumi; M Smacchia; F Grignani; C Riccardi; I Nicoletti
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.

Authors:  J A Plumb; P Workman
Journal:  Int J Cancer       Date:  1994-01-02       Impact factor: 7.396

Review 7.  Tumour hypoxia: the picture has changed in the 1990s.

Authors:  J M Brown; A J Giaccia
Journal:  Int J Radiat Biol       Date:  1994-01       Impact factor: 2.694

8.  In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.

Authors:  R M Phillips; P B Hulbert; M C Bibby; N R Sleigh; J A Double
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

9.  Enhanced synthesis of stress proteins caused by hypoxia and relation to altered cell growth and metabolism.

Authors:  C S Heacock; R M Sutherland
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

Review 10.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

View more
  10 in total

1.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

Authors:  Andrew J Leiker; William DeGraff; Rajani Choudhuri; Anastasia L Sowers; Angela Thetford; John A Cook; Carter Van Waes; James B Mitchell
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.

Authors:  Jasti S Rao; Christopher Gondi; Chandramu Chetty; Subramanyam Chittivelu; Pushpa A Joseph; Sajani S Lakka
Journal:  Mol Cancer Ther       Date:  2005-09       Impact factor: 6.261

Review 3.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 4.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

5.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

6.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

7.  Hydrogen peroxide- and cell-density-regulated expression of NADH-cytochrome b5 reductase in HeLa cells.

Authors:  Rosario I Bello; Francisco J Alcaín; Consuelo Gómez-Díaz; Guillermo López-Lluch; Plácido Navas; José M Villalba
Journal:  J Bioenerg Biomembr       Date:  2003-04       Impact factor: 2.945

8.  A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs.

Authors:  H R Mellor; D J P Ferguson; R Callaghan
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

9.  Multilayered Cultures of NSCLC cells grown at the Air-Liquid Interface allow the efficacy testing of inhaled anti-cancer drugs.

Authors:  Dania Movia; Despina Bazou; Yuri Volkov; Adriele Prina-Mello
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

10.  Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice.

Authors:  T Takechi; H Okabe; A Fujioka; Y Murakami; M Fukushima
Journal:  Jpn J Cancer Res       Date:  1998-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.